Duration of adjuvant chemotherapy for colon cancer and survival among the elderly

Journal of Clinical Oncology

Volumn 24, Issue 15, 2006, Pages 2368-2375

  Neugut, Alfred I ^a   Matasar, Matthew ^a   Wang, Xiaoyan ^a   McBride, Russell ^a   Jacobson, Judith S ^a   Tsai, Wei Yann ^a   Grann, Victor R ^a   Hershman, Dawn L ^a  

^a

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; AGE; CANCER REGISTRY; COLON TUMOR; DATA BASE; FEMALE; MALE; MEDICARE; MORTALITY; SURVIVAL; TIME; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DATABASES; FEMALE; FLUOROURACIL; HUMANS; MALE; MEDICARE; SEER PROGRAM; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 33744831506     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.5005     Document Type: Article

References (56)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials - Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942, 1998
2. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
3. O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300, 1998
4. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
5. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
6. Hryniuk W: Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 91:1425, 1999
7. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211, 1998
8. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 21:4524-4531, 2003
9. Bickell NA, McEvoy MD: Physicians' reasons for failing to deliver effective breast cancer care: A framework for underuse. Med Care 41:442-446, 2003
10. Hershman D, McBride R, Jacobson JS, et al: Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23:6639-6646, 2005
11. Weir HK, Thun MJ, Hankey BF, et al: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:1276-1299, 2003
12. Boyle P, Leon ME: Epidemiology of colorectal cancer. Br Med Bull 64:1-25, 2002
13. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
14. Hawk ET, Limburg PJ, Viner JL: Epidemiology and prevention of colorectal cancer. Surg Clin North Am 82:905-941, 2002
15. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, 1999
16. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-944, 1995
17. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
18. Sundararajan V, Grann VR, Jacobson JS, et al: Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population-based study. Cancer J 7:213-218, 2001
19. Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136: 349-357, 2002
20. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
21. Engstrom PF, Benson AB III, Cohen A, et al: NCCN Colorectal Cancer Practice Guidelines: The National Comprehensive Cancer Network. Oncology (Huntingt) 10:140-175, 1996
22. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
23. Warren JL, Harlan LC, Fahey A, et al: Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40:IV-55-61, 2002 (8 suppl)
24. Lamont EB, Lauderdale DS, Schilsky RL, et al: Construct validity of Medicare chemotherapy claims: The case of 5FU. Med Care 40:201-211, 2002
25. Bach PB, Guadagnoli E, Schrag D, et al: Patient demographic and socioeconomic characteristics in the SEER-Medicare database: Applications and limitations. Med Care 40:IV-19-25, 2002 (8 suppl)
26. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
27. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
28. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000
29. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
30. Balkrishnan R: Predictors of medication adherence in the elderly. Clin Ther 20:764-771, 1998
31. Stone VE, Hogan JW, Schuman P, et al: Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HER study. J Acquir Immune Defic Syndr 28:124-131, 2001
32. Ahn JB, Shim KY, Jeung HC, et al: Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. Cancer Lett 167:215-224, 2001
33. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
34. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
35. Poplin EA, Benedetti JK, Estes NC, et al: Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23:1819-1825, 2005
36. Chau I, Norman AR, Cunningham D, et al: A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16:549-557, 2005
37. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
38. Lyman GH, Dale DC, Friedberg J, et al: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J Clin Oncol 22:4302-4311, 2004
39. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003
40. Silliman RA, Guadagnoli E, Rakowski W, et al: Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol 20:2680-2688, 2002
41. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
42. Murri R, Ammassari A, Trotta MP, et al: Patient-reported and physician-estimated adherence to HAART: Social and clinic center-related factors are associated with discordance. J Gen Intern Med 19:1104-1110, 2004
43. Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462-467, 2002
44. Waeber B, Leonetti G, Kolloch R, et al: Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 17: 1041-1045, 1999
45. Misdrahi D, Llorca PM, Lancon C, et al: Compliance in schizophrenia: Predictive factors, therapeutical considerations and research implications. Encephale 28:266-272, 2002
46. McDonnell PJ, Jacobs MR: Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36:1331-1336, 2002
47. Horwitz RI, Horwitz SM: Adherence to treatment and health outcomes. Arch Intern Med 153: 1863-1868, 1993
48. van Servellen G, Chang B, Garcia L, et al: Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 16:269-281, 2002
49. Lacro JP, Dunn LB, Dolder CR, et al: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 63:892-909, 2002
50. Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63: 1121-1128, 2002
51. Okuno J, Yanagi H, Tomura S: Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol 57:589-594, 2001
52. Cramer J, Rosenheck R, Kirk G, et al: Medication compliance feedback and monitoring in a clinical trial: Predictors and outcomes. Value Health 6:566-573, 2003
53. Haynes RB, McDonald HP, Garg AX: Helping patients follow prescribed treatment: Clinical applications. JAMA 288:2880-2883, 2002
54. Fink AK, Gurwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315, 2004
55. Allegra C, Sargent DJ: Adjuvant therapy for colon cancer: The pace quickens. N Engl J Med 352:2746-2748, 2005
56. O'Connell MJ: Current status of adjuvant therapy for colorectal cancer. Oncology (Huntingt) 18: 751-758, 2004